We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.
- Authors
Chawla, Sant P; Staddon, Arthur P; Baker, Laurence H; Schuetze, Scott M; Tolcher, Anthony W; D'Amato, Gina Z; Blay, Jean-Yves; Mita, Monica M; Sankhala, Kamalesh K; Berk, Lori; Rivera, Victor M; Clackson, Tim; Loewy, John W; Haluska, Frank G; Demetri, George D
- Abstract
Ridaforolimus is an inhibitor of mammalian target of rapamycin, an integral component of the phosphatidyl 3-kinase/AKT signaling pathway, with early evidence of activity in sarcomas. This multicenter, open-label, single-arm, phase II trial was conducted to assess the antitumor activity of ridaforolimus in patients with distinct subtypes of advanced sarcomas.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Vol 30, Issue 1, p78
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2011.35.6329